Opendata, web and dolomites

Pituitary enhancers SIGNED

Identification and functional validation of novel enhancer sequences involved in pituitary gland development and pathology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Pituitary enhancers project word cloud

Explore the words cloud of the Pituitary enhancers project. It provides you a very rough idea of what is the project "Pituitary enhancers" about.

duplications    expression    reporter    causing    gene    cnv    regulates    perform    mechanisms    structural    lag    gpr10    sanger    underlying    pathological    regulatory    physiological    children    transcription    performed    there    silico    enhancer    normal    hypothesis    tumoral    interactions    validate    genome    screen    cells    gpr101    chromatin    variations    health    duplicated    conducting    sequences    regulation    functional    fundamental    assays    sequencing    overexpression    mutations    promoter    novo    verified    local    pursuing    disorders    seq    acrogigantism    remarkably    showing    tumors    histone    abnormal    clinical    region    human    profile    accessibility    creation    tested    patients    disrupt    preliminary    4c    methylation    enhancers    transcriptional    structure    vitro    luciferase    gap    central    molecular    place    indicator    elucidate    characterization    pituitary    pathologies    located    functionally    linked    chip    domain    marks    putative    de   

Project "Pituitary enhancers" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS MIRASOLE SPA 

Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100
website: www.humanitas.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-03-16   to  2022-03-15

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 183˙473.00

Map

 Project objective

There is a fundamental gap in understanding how the GPR101 gene regulates human growth in physiological and pathological conditions. Children’s growth is remarkably clinical relevant and is an important indicator of their health and general well-being. The specific objective of this proposal is to identify the molecular mechanisms underlying GPR101 overexpression in the pituitary tumors of children with GPR101 duplications causing X-linked acrogigantism (X-LAG). My central hypothesis is that GPR101 duplications disrupt the structure of the local chromatin, leading to the creation of a new chromatin domain where de novo enhancer-promoter interactions take place, causing abnormal GPR101 expression. This hypothesis will be tested by pursuing three specific aims: 1. Elucidate the transcriptional regulation of GPR101 in normal and pathological conditions 2. Identify and functionally characterize novel pituitary-specific enhancer sequences 3. Investigate these regulatory sequences in patients with different pituitary pathologies. To achieve aim 1) I will perform an in vitro functional characterization of GPR101 promoter: promoter activity will be studied by luciferase-based reporter assays, by conducting a methylation analysis, and by determining its accessibility to transcription factors. To achieve aim 2) I will validate my preliminary results showing the formation of a novel chromatin domain by 4C-Seq. Four putative enhancer sequences located within the duplicated GPR10 region and identified in silico will be functionally evaluated in vitro to establish their impact on transcriptional activity. To identify novel pituitary-specific enhancers, a whole-genome profile of enhancer-specific histone marks will be performed in normal and tumoral pituitary cells by ChIP-Seq. To achieve aim 3) I will screen patients with different pituitary disorders for mutations (Sanger sequencing) and structural variations (CNV assays) in the functionally-verified enhancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PITUITARY ENHANCERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PITUITARY ENHANCERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ASIQS (2019)

Antiferromagnetic spintronics investigated by quantum sensing techniques

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More